Hillstream BioPharma Announces Participation at the 2019 ASCO Annual Meeting, May 31-June 4, 2019, McCormick Place, Chicago, IL
May 20, 2019
Chester, N.J., May 20, 2019 – Hillstream BioPharma Inc. (“Hillstream”), a development-stage company advancing improved therapies for patients with cancer, today announced it intends to have a presence at the 2019 ASCO Annual Meeting, May 31-June 4, 2019 at McCormick Place, Chicago, IL.
Event: 2019 ASCO Annual Meeting
Date: Friday, May 31, 2019 – Tuesday, June 4, 2019
Time: 8:00am – 6:00pm CDT
Location: McCormick Place, Chicago, IL
Hillstream’s Chief Executive Officer, Randy Milby, will be available to provide an overview of the company’s business and scientific pipeline during the Annual Meeting. Hillstream will also be available for outside meetings with investors and members of the scientific and business communities who are located in the Chicago area.
If you are an investor and would like to attend the 2019 ASCO Annual Meeting , please click on the following link (https://meetings.asco.org/am/attend-meeting) to register. To book an appointment with Hillstream’s management, please contact Jennifer K. Zimmons, Ph.D., at +1 917.214.3514 or email@example.com.
About Hillstream BioPharma Inc.
Hillstream BioPharma Inc. (“Hillstream”) is a development-stage company advancing improved therapies for patients with cancer. Hillstream’s competitive advantage is to enhance the safety and efficacy of oncology therapies by encapsulating them in a polymeric injectable suspension comprised of FDA-recognized inactive ingredients. Encapsulation ensures delivery within the tumor cells and prevents free drug levels in circulation that can cause toxicity. The slow and sustained release of the therapy may also reduce the frequency of dosing while maintaining its efficacy. The novel formulation allows Hillstream to build a strong patent estate and seek FDA Orphan Drug Designation in specific indications.
Hillstream’s proprietary formulations of bortezomib, tumor necrosis factor – alpha and salinomycin are currently in preclinical development for cancers with significant unmet need. By taking advantage of the FDA’s 505(b)(2) regulatory pathway for bortezomib and paclitaxel, the Company could expedite the development process and bring these novel formulations to market to offer patients hope. For more information, please visit www.hillstreambio.com.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
Hillstream BioPharma Inc.
President & CEO
Jennifer K. Zimmons, Ph.D.
Zimmons International Communications
Tel: +1 917.214.3514
Source: Hillstream BioPharma Inc.